• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

90.00 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Discover the top movers in Friday's pre-market session. ↗
May 23, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
May 22, 2025
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
May 15, 2025
From Merus N.V.
Via GlobeNewswire
News headline image
What's Going On With Merus Stock Monday? ↗
January 13, 2025
Merus announced a research collaboration and license agreement with Biohaven. 
Via Benzinga
News headline image
Merus to Present at BofA Securities 2025 Health Care Conference
May 08, 2025
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
May 07, 2025
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
April 23, 2025
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
February 27, 2025
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Present at Upcoming Investor Conferences
February 25, 2025
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Shares Are Up Today: What's Going On? ↗
February 18, 2025
Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for... 
Via Benzinga
News headline image
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
February 18, 2025
This marks the second BTD for petosemtamab in HNSCC 
From Merus N.V.
Via GlobeNewswire
News headline image
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
February 13, 2025
 
Via Benzinga
News headline image
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
February 13, 2025
From Merus N.V.
Via GlobeNewswire
News headline image
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
February 05, 2025
From Merus N.V.
Via GlobeNewswire
News headline image
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
January 12, 2025
From Merus N.V.
Via GlobeNewswire
News headline image
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday ↗
January 10, 2025
 
Via Benzinga
News headline image
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
December 16, 2024
From Merus N.V.
Via GlobeNewswire
News headline image
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
December 07, 2024
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Scores Its First FDA Approval For Lung Cancer Drug ↗
December 05, 2024
FDA approves Merus' Bizengri as the first treatment for advanced NRG1 fusion-positive cancers. U.S. peak sales are estimated at $16.5 million. 
Via Benzinga
News headline image
Jim Cramer: This Health Care Stock Is 'Very, Very Speculative' ↗
December 05, 2024
Jim Cramer called Allison Transmission a "storied company... terrific. It does great." 
Via Benzinga
News headline image
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
December 04, 2024
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline ↗
December 02, 2024
Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key focus for analysts. 
Via Benzinga
News headline image
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday ↗
December 02, 2024
 
Via Benzinga
News headline image
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
December 02, 2024
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
December 01, 2024
From Merus N.V.
Via GlobeNewswire
News headline image
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
November 21, 2024
 
Via Benzinga
News headline image
Merus to Present at Upcoming Investor Conferences
November 06, 2024
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Receives FDA extension of PDUFA for zenocutuzumab
November 05, 2024
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
October 31, 2024
From Merus N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap